Sugi Predict

Sugi Predict / Targets / LPAR2

LPAR2

Lysophosphatidic acid receptor 2 · Q9HBW0 · LPAR2 on Sugi Atlas →

94,083 patent compounds predicted against LPAR2, 55,658 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Thiophosphoric Acid Dodecyl Ester Thiophosphoric Acid Dodecyl Ester (SCHEMBL40052) 1.00 15/20
SCHEMBL40320 SCHEMBL40320 1.00 15/20
SCHEMBL40048 SCHEMBL40048 0.75 15/20
SCHEMBL39671 SCHEMBL39671 0.60 13/20
SCHEMBL36045 SCHEMBL36045 0.59 13/20
SCHEMBL35944 SCHEMBL35944 0.58 13/20
SCHEMBL36110 SCHEMBL36110 0.58 13/20
SCHEMBL40063 SCHEMBL40063 0.67 12/20
SCHEMBL40088 SCHEMBL40088 0.67 12/20
SCHEMBL35831 SCHEMBL35831 0.58 11/20
SCHEMBL29136 SCHEMBL29136 1.00 10/20
SCHEMBL27821 SCHEMBL27821 0.95 10/20
SCHEMBL37004 SCHEMBL37004 0.95 10/20
SCHEMBL35789 SCHEMBL35789 0.57 10/20
SCHEMBL51678 SCHEMBL51678 0.57 9/20
SCHEMBL51910 SCHEMBL51910 0.57 9/20
SCHEMBL52233 SCHEMBL52233 0.57 9/20
SCHEMBL52236 SCHEMBL52236 0.57 9/20
SCHEMBL52367 SCHEMBL52367 0.57 9/20
SCHEMBL52384 SCHEMBL52384 0.57 9/20

Clinical trials — most relevant to LPAR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis PHASE4COMPLETED
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Treatment Strategies in CHS PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) PHASE1/PHASE2COMPLETED
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Assessment of Coronary Plaque Composition PHASE1COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Pro-Resolving Mediators in Acute Inflammation in Humans EARLY_PHASE1COMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease nanRECRUITING
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Clinical Study Evaluating the Effect of Losartan nanRECRUITING
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Fat-induced Release of GLP-1 in Humans nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
LDL-Apheresis for FSGS CardioRenal Outcomes nanCOMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a LPAR2 binder may also engage these)

ProteinNameSimilarity
Q95KH4 — 1.000 Q95KH4 →
Q9JL06 — 0.997 Q9JL06 →
Q9Z0L1 — 0.976 Q9Z0L1 →
P47752 — 0.975 P47752 →
P11617 — 0.973 P11617 →
LPAR1 Lysophosphatidic acid receptor 1 0.973 landscape →
Q864I2 — 0.972 Q864I2 →
S1PR4 Sphingosine 1-phosphate receptor 4 0.971 landscape →
Q8C206 — 0.971 Q8C206 →
P31387 — 0.970 P31387 →
O55040 — 0.970 O55040 →
Q9PU17 — 0.970 Q9PU17 →
P52592 — 0.969 P52592 →
MTNR1B Melatonin receptor type 1B 0.969 landscape →
Q6A155 — 0.969 Q6A155 →
NMUR1 Neuromedin-U receptor 1 0.969 landscape →
Q28031 — 0.968 Q28031 →
Q80T02 — 0.968 Q80T02 →
P61793 — 0.968 P61793 →
P56448 — 0.968 P56448 →
P61794 — 0.968 P61794 →
P70310 — 0.968 P70310 →
P46628 — 0.967 P46628 →
Q80SS6 — 0.967 Q80SS6 →
Q864K7 — 0.967 Q864K7 →
Q9JJI5 — 0.967 Q9JJI5 →
Q60613 — 0.967 Q60613 →
P46616 — 0.967 P46616 →
NTSR2 Neurotensin receptor type 2 0.967 landscape →
P35365 — 0.966 P35365 →